1. Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers
- Author
-
Kevin J. Tam, Christopher J. Ong, Ivy Z F Jiao, and Daniel H F Hui
- Subjects
Male ,Cell signaling ,semaphorins ,Neuropilins ,neuropilins ,Antineoplastic Agents ,Review ,Malignancy ,Catalysis ,lcsh:Chemistry ,Inorganic Chemistry ,03 medical and health sciences ,Prostate cancer ,cancer therapeutics ,0302 clinical medicine ,Semaphorin ,Prostate ,inhibitors ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Autocrine signalling ,lcsh:QH301-705.5 ,Molecular Biology ,Spectroscopy ,030304 developmental biology ,Cell Proliferation ,0303 health sciences ,business.industry ,Organic Chemistry ,Cancer ,plexins ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,3. Good health ,Computer Science Applications ,medicine.anatomical_structure ,lcsh:Biology (General) ,lcsh:QD1-999 ,030220 oncology & carcinogenesis ,SEMA3C ,Cancer research ,business - Abstract
The semaphorins represent a large family of signaling molecules with crucial roles in neuronal and cardiac development. While normal semaphorin function pertains largely to development, their involvement in malignancy is becoming increasingly evident. One member, Semaphorin 3C (SEMA3C), has been shown to drive a number of oncogenic programs, correlate inversely with cancer prognosis, and promote the progression of multiple different cancer types. This report surveys the body of knowledge surrounding SEMA3C as a therapeutic target in cancer. In particular, we summarize SEMA3C’s role as an autocrine andromedin in prostate cancer growth and survival and provide an overview of other cancer types that SEMA3C has been implicated in including pancreas, brain, breast, and stomach. We also propose molecular strategies that could potentially be deployed against SEMA3C as anticancer agents such as biologics, small molecules, monoclonal antibodies and antisense oligonucleotides. Finally, we discuss important considerations for the inhibition of SEMA3C as a cancer therapeutic agent.
- Published
- 2019